PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China
· Delayed Price · Currency is CNY 37.67
+0.78 (2.11%)
Mar 10, 2026, 2:25 PM CST
SHE:300725 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 1,977 | 1,686 | 1,725 | 1,594 | 1,201 | 1,022 | Upgrade
|
| Other Revenue | 3.09 | 3.09 | 0.45 | 0.49 | 0.36 | 0.13 | Upgrade
|
| Revenue | 1,980 | 1,689 | 1,725 | 1,595 | 1,202 | 1,022 | Upgrade
|
| Revenue Growth (YoY) | 26.78% | -2.12% | 8.18% | 32.71% | 17.55% | 54.36% | Upgrade
|
| Cost of Revenue | 1,406 | 1,106 | 1,018 | 878.71 | 632.85 | 556.44 | Upgrade
|
| Gross Profit | 573.89 | 582.74 | 707.2 | 715.99 | 568.78 | 465.79 | Upgrade
|
| Selling, General & Admin | 233 | 238.47 | 253.44 | 248.49 | 174.63 | 151.83 | Upgrade
|
| Research & Development | 97.41 | 107.33 | 169.17 | 168.32 | 114.02 | 90.93 | Upgrade
|
| Other Operating Expenses | -1.72 | 6.4 | 14.8 | 11.89 | 8.28 | 6.37 | Upgrade
|
| Operating Expenses | 328.67 | 356.1 | 447.24 | 435.78 | 299.34 | 253.98 | Upgrade
|
| Operating Income | 245.23 | 226.64 | 259.95 | 280.21 | 269.44 | 211.81 | Upgrade
|
| Interest Expense | -50.8 | -60.91 | -66.1 | -45.72 | -9.18 | -0.63 | Upgrade
|
| Interest & Investment Income | 40.52 | 45.76 | 24.79 | 26.7 | 249.42 | 6.67 | Upgrade
|
| Currency Exchange Gain (Loss) | 23.65 | 23.65 | 0.46 | 34.45 | -16.92 | -23.64 | Upgrade
|
| Other Non Operating Income (Expenses) | -11.74 | -2.96 | 4.58 | -0.92 | 13.47 | -0.08 | Upgrade
|
| EBT Excluding Unusual Items | 246.86 | 232.19 | 223.69 | 294.72 | 506.23 | 194.13 | Upgrade
|
| Impairment of Goodwill | -0.44 | -0.44 | - | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.34 | 9.36 | -21.33 | 1.99 | 1.67 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | 0.42 | - | 0.04 | - | Upgrade
|
| Asset Writedown | -25.7 | -0.96 | -14.8 | -4.38 | -0.17 | -0.18 | Upgrade
|
| Other Unusual Items | 8.75 | 8.75 | 33.4 | 30.94 | - | 10.56 | Upgrade
|
| Pretax Income | 229.13 | 248.9 | 221.38 | 323.26 | 507.77 | 204.5 | Upgrade
|
| Income Tax Expense | 27.99 | 29.36 | 24.01 | -2.63 | 4 | 20.3 | Upgrade
|
| Earnings From Continuing Operations | 201.14 | 219.54 | 197.36 | 325.89 | 503.77 | 184.2 | Upgrade
|
| Minority Interest in Earnings | - | - | 0 | -11.67 | -17.21 | 0 | Upgrade
|
| Net Income | 201.14 | 219.54 | 197.36 | 314.22 | 486.56 | 184.21 | Upgrade
|
| Net Income to Common | 201.14 | 219.54 | 197.36 | 314.22 | 486.56 | 184.21 | Upgrade
|
| Net Income Growth | 14.87% | 11.24% | -37.19% | -35.42% | 164.14% | 21.13% | Upgrade
|
| Shares Outstanding (Basic) | 201 | 200 | 199 | 199 | 198 | 186 | Upgrade
|
| Shares Outstanding (Diluted) | 201 | 200 | 201 | 200 | 199 | 188 | Upgrade
|
| Shares Change (YoY) | 0.31% | -0.90% | 0.62% | 0.37% | 6.09% | 0.79% | Upgrade
|
| EPS (Basic) | 1.00 | 1.10 | 0.99 | 1.58 | 2.46 | 0.99 | Upgrade
|
| EPS (Diluted) | 1.00 | 1.10 | 0.98 | 1.57 | 2.44 | 0.98 | Upgrade
|
| EPS Growth | 14.51% | 12.25% | -37.58% | -35.66% | 148.98% | 20.19% | Upgrade
|
| Free Cash Flow | 555 | 184.7 | -68.93 | -311.3 | -267.73 | 196.33 | Upgrade
|
| Free Cash Flow Per Share | 2.76 | 0.93 | -0.34 | -1.55 | -1.34 | 1.04 | Upgrade
|
| Dividend Per Share | 0.280 | 0.280 | 0.310 | 0.100 | 0.100 | 0.077 | Upgrade
|
| Dividend Growth | -9.68% | -9.68% | 210.00% | - | 30.04% | -33.36% | Upgrade
|
| Gross Margin | 28.99% | 34.51% | 40.99% | 44.90% | 47.33% | 45.57% | Upgrade
|
| Operating Margin | 12.39% | 13.42% | 15.07% | 17.57% | 22.42% | 20.72% | Upgrade
|
| Profit Margin | 10.16% | 13.00% | 11.44% | 19.70% | 40.49% | 18.02% | Upgrade
|
| Free Cash Flow Margin | 28.03% | 10.94% | -4.00% | -19.52% | -22.28% | 19.21% | Upgrade
|
| EBITDA | 384.84 | 355.41 | 374.25 | 366.45 | 322.64 | 236.28 | Upgrade
|
| EBITDA Margin | 19.44% | 21.05% | 21.69% | 22.98% | 26.85% | 23.11% | Upgrade
|
| D&A For EBITDA | 139.62 | 128.77 | 114.3 | 86.24 | 53.2 | 24.47 | Upgrade
|
| EBIT | 245.23 | 226.64 | 259.95 | 280.21 | 269.44 | 211.81 | Upgrade
|
| EBIT Margin | 12.39% | 13.42% | 15.07% | 17.57% | 22.42% | 20.72% | Upgrade
|
| Effective Tax Rate | 12.22% | 11.79% | 10.85% | - | 0.79% | 9.93% | Upgrade
|
| Revenue as Reported | 1,980 | 1,689 | 1,725 | 1,595 | 1,202 | 1,022 | Upgrade
|
| Advertising Expenses | - | 1.44 | 1.93 | 0.93 | 0.6 | 0.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.